These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 18671472

  • 1. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).
    Philis-Tsimikas A.
    Expert Opin Pharmacother; 2008 Aug; 9(12):2181-95. PubMed ID: 18671472
    [Abstract] [Full Text] [Related]

  • 2. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.
    Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
    [Abstract] [Full Text] [Related]

  • 3. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K.
    Vasc Health Risk Manag; 2010 Jun 01; 6():399-410. PubMed ID: 20539842
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
    Chapman TM, Perry CM.
    BioDrugs; 2005 Jun 01; 19(1):67-9. PubMed ID: 15691219
    [Abstract] [Full Text] [Related]

  • 6. Insulin detemir: a long-acting insulin product.
    Jones MC, Patel M.
    Am J Health Syst Pharm; 2006 Dec 15; 63(24):2466-72. PubMed ID: 17158694
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr 15; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 9. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P, Cosson E.
    Diabetes Metab; 2005 Sep 15; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH, Nattrass M, Pieber TR.
    Diabetes Metab Res Rev; 2007 Sep 15; 23(6):441-54. PubMed ID: 17668418
    [Abstract] [Full Text] [Related]

  • 12. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.
    Diabetes Care; 2006 Jun 15; 29(6):1269-74. PubMed ID: 16732007
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Insulin detemir: a new basal insulin analogue.
    Soran H, Younis N.
    Diabetes Obes Metab; 2006 Jan 15; 8(1):26-30. PubMed ID: 16367879
    [Abstract] [Full Text] [Related]

  • 15. Insulin detemir: from concept to clinical experience.
    Home P, Kurtzhals P.
    Expert Opin Pharmacother; 2006 Feb 15; 7(3):325-43. PubMed ID: 16448327
    [Abstract] [Full Text] [Related]

  • 16. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
    Davies MJ, Derezinski T, Pedersen CB, Clauson P.
    Diabetes Technol Ther; 2008 Aug 15; 10(4):273-7. PubMed ID: 18715200
    [Abstract] [Full Text] [Related]

  • 17. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE.
    Curr Med Res Opin; 2006 Dec 15; 22(12):2613-9. PubMed ID: 17166343
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
    Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M.
    Diabetes Care; 2001 Feb 15; 24(2):296-301. PubMed ID: 11213882
    [Abstract] [Full Text] [Related]

  • 19. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S, PREDICTIVE Turkey Study Group.
    Pediatr Diabetes; 2009 Sep 15; 10(6):401-7. PubMed ID: 19220776
    [Abstract] [Full Text] [Related]

  • 20. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov 15; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.